Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation

Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

(2020) Paul K. Paik et al.   NEW ENGLAND JOURNAL OF MEDICINE

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

(2020) Jürgen Wolf et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

(2019) Gerald S. Falchook et al.   CLINICAL CANCER RESEARCH

Leptomeningeal metastases in non-small-cell lung cancer

(2018) Haiying Cheng et al.   LANCET ONCOLOGY

Alectinib for Patients with ALK Rearrangement–Positive Non–Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401)

(2017) Eiji Iwama et al.   Journal of Thoracic Oncology

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

(2014) Tatsushi Kodama et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

(2012) Yosuke Togashi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy

(2009) Akira Inoue et al.   JOURNAL OF CLINICAL ONCOLOGY